Clinical Trial Update: Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ [Phase 4]

View source ↗

Summary

Phase 4 open-label study assessing patient satisfaction and symptom improvement in male hypogonadism treated with Natesto.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism

Drugs mentioned

• NATESTO (testosterone)

Snippet

Sponsor: Acerus Pharmaceuticals Corporation | Conditions: Hypogonadism | Phase 4 | Status: COMPLETED | Results posted: 2019-08-12